Phenytoin

Summary

Phenytoin (CHEMBL16) is an approved small-molecule anticonvulsant (ATC N03AB02) targeting SCN2A; indicated across 18 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AB02 (+1 more)
• Targets: 1 (SCN2A)
• Indications: 18 conditions
• Clinical trials: 63
• Chemistry: 252.27 Da · C15H12N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL16
Name	Phenytoin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	1775
ChEBI	CHEBI:8107
ATC	N03AB02, N03AB52
Molecular formula	C15H12N2O2
Molecular weight	252.27
InChIKey	CXOFVDLJLONNDW-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3

IUPAC name: 5,5-diphenylimidazolidine-2,4-dione

ChEBI definition: A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.

Pharmacological roles (ChEBI): anticonvulsant, teratogenic agent, drug allergen, sodium channel blocker.

Also known as: Dilantin, Dilantin-125, Dilantin-30, Diphenylhydantoin, Dilabid, Epamin, Fenitoina, Hydantol, Lepitoin, NSC-8722, Phenytoin, PHENYTOIN COMPONENT OF SM-88

Parent form; salt/anhydrous children: CHEMBL1611, CHEMBL553532, CHEMBL3274483

Patent coverage: 16,104 distinct patent families (53,375 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SCN2A	Nav1.2	Pore blocker	4.9	0.1%	Q99250

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Fructose-bisphosphate aldolase, RecQ-like DNA helicase BLM, Inositol monophosphatase 1, Endonuclease 4, Peripheral myelin protein 22, Sodium channel protein type 5 subunit alpha, Sodium channel protein type 4 subunit alpha, Sodium channel alpha subunits; brain (Types I, II, III), Voltage-gated L-type calcium channel, Sodium channel alpha subunits; brain (Types I, II, III), 5-hydroxytryptamine receptor 2A, Histamine H1 receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M1, Cytochrome P450 2C9, Sodium channel protein type 2 subunit alpha, Aldehyde dehydrogenase 1A1, Sodium channel protein type 2 subunit alpha.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 30 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BLM	8.66	Potency	2.2	nM	CHEMBL_ACT_4750049
BLM	8.66	Potency	2.2	nM	CHEMBL_ACT_4941792
P08482	5.85	Potency	1412	nM	CHEMBL_ACT_4807516
P97697	5.3	Potency	5012	nM	CHEMBL_ACT_4420320
CYP2C9	5.22	Ki	6000	nM	CHEMBL_ACT_371809
HRH1	5.21	AC50	6100	nM	CHEMBL_ACT_25212189
HTR2A	5.2	AC50	6262	nM	CHEMBL_ACT_25173505
P51450	5.2	Potency	6310	nM	CHEMBL_ACT_4955883
P0A6C1	5.1	Potency	7943	nM	CHEMBL_ACT_4069617
CYP2C9	5	Ki	10000	nM	CHEMBL_ACT_1119262
P08482	5	Potency	10000	nM	CHEMBL_ACT_4857827

Target pathways

Aggregated over 1 target gene(s): SCN2A.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
Developmental Biology	1	SCN2A
L1CAM interactions	1	SCN2A
Muscle contraction	1	SCN2A
Axon guidance	1	SCN2A
Interaction between L1 and Ankyrins	1	SCN2A
Cardiac conduction	1	SCN2A
Phase 0 - rapid depolarisation	1	SCN2A
Nervous system development	1	SCN2A
Sensory Perception	1	SCN2A
Sensory perception of taste	1	SCN2A
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	SCN2A

Dominant GO biological processes

GO term	Targets
sodium ion transport	1
nervous system development	1
memory	1
intrinsic apoptotic signaling pathway in response to osmotic stress	1
neuronal action potential	1
sodium ion transmembrane transport	1
myelination	1
neuron apoptotic process	1
cellular response to hypoxia	1
cardiac muscle cell action potential involved in contraction	1
action potential	1
regulation of heart rate	1
monoatomic ion transport	1
monoatomic ion transmembrane transport	1
regulation of membrane potential	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
visual epilepsy	4	MONDO:0001386	HP:0001250

15 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
injury	2	MONDO:0021178	EFO:0000546
optic neuritis	2	MONDO:0005885	EFO:0007405
thalassemia	2	MONDO:0000984	EFO:1001996
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
polyneuropathy	2	MONDO:0001824	EFO:0009562
sickle cell disease	2	MONDO:0011382	MONDO:0011382
cocaine dependence	1	MONDO:0005186	EFO:0002610
leukemia	1	MONDO:0005059	EFO:0000565
lymphoma	1	MONDO:0005062	EFO:0000574
neuroblastoma	1	MONDO:0005072	EFO:0000621
anemia	1	MONDO:0002280	EFO:0004272
immune system disorder	1	MONDO:0005046	EFO:0000540

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 63.

Phase distribution

Phase	Trials
PHASE1	21
PHASE4	12
Not specified	12
PHASE2	8
PHASE3	4
PHASE2/PHASE3	3
PHASE1/PHASE2	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07072624	PHASE4	RECRUITING	Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)
NCT00146237	PHASE4	COMPLETED	Phenytoin as an Augmentation for SSRI Failures
NCT00366067	PHASE4	COMPLETED	Study of Efficacy of Phenytoin in Therapy of Children With Bronchial Asthma
NCT00510783	PHASE4	COMPLETED	IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
NCT00581893	PHASE4	COMPLETED	Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00618436	PHASE4	COMPLETED	Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
NCT01478035	PHASE4	TERMINATED	Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
NCT02409433	PHASE4	TERMINATED	Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management
NCT04176887	PHASE4	UNKNOWN	Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus
NCT04967326	PHASE4	COMPLETED	Role of Clinical Pharmacists in Epilepsy Management
NCT05697614	PHASE4	UNKNOWN	The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
NCT04573803	PHASE3	NOT_YET_RECRUITING	Pharmacological Management of Seizures Post Traumatic Brain Injury
NCT07590375	PHASE2/PHASE3	NOT_YET_RECRUITING	Topical Phenytoin for Management of Gingival Recession
NCT00004817	PHASE3	COMPLETED	Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
NCT00210782	PHASE3	COMPLETED	A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT03512756	PHASE2/PHASE3	TERMINATED	A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
NCT04647877	PHASE2/PHASE3	COMPLETED	Phenytoin Cream for the Treatment of Neuropathic Pain
NCT05637086	PHASE2	RECRUITING	Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
NCT00040469	PHASE2	TERMINATED	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT00245037	PHASE1/PHASE2	COMPLETED	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00801931	PHASE1/PHASE2	TERMINATED	Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
NCT01187719	PHASE2	COMPLETED	The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance
NCT01451593	PHASE2	COMPLETED	Neuroprotection With Phenytoin in Optic Neuritis
NCT01730313	PHASE2	WITHDRAWN	Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012
NCT02088957	PHASE2	TERMINATED	Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
NCT02413658	PHASE2	UNKNOWN	Phenytoin in the Healing of Clean Surgical Wounds
NCT02939937	PHASE2	COMPLETED	Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
NCT07590102	PHASE1	NOT_YET_RECRUITING	A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
NCT00000285	PHASE1	COMPLETED	Effects of Phenytoin on Cocaine Use in Humans - 2
NCT00627575	PHASE1	COMPLETED	AED/Statin Interaction Study
NCT01122953	PHASE1	COMPLETED	Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions
NCT01635829	PHASE1	COMPLETED	A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir
NCT01680042	PHASE1	UNKNOWN	Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy
NCT01878578	PHASE1	TERMINATED	The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients
NCT02283827	PHASE1	COMPLETED	Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
NCT02707965	PHASE1	COMPLETED	Characterization of Epilepsy Patients BEEP 2b
NCT04845646	PHASE1	COMPLETED	DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
NCT04981704	PHASE1	COMPLETED	A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
NCT05901714	PHASE1	COMPLETED	A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
NCT05995249	PHASE1	COMPLETED	A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
NCT06466473	PHASE1	COMPLETED	A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults
NCT06543043	PHASE1	COMPLETED	A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
NCT06633185	PHASE1	COMPLETED	Effect of Phenytoin Cream on Wound Healing After Anal Fissure Surgery.
NCT06719557	PHASE1	COMPLETED	A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)
NCT06903715	PHASE1	COMPLETED	A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
NCT06906809	PHASE1	COMPLETED	Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
NCT06919991	PHASE1	COMPLETED	Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
NCT07066722	PHASE1	COMPLETED	A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults
NCT00598923	EARLY_PHASE1	TERMINATED	Preventing Epilepsy After Traumatic Brain Injury With Topiramate
NCT00162474	Not specified	RECRUITING	Determinants of Warfarin Metabolism
NCT00004403	Not specified	COMPLETED	Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
NCT00226538	Not specified	COMPLETED	Prediction of Drug Interactions With CYP2C9 Substrates
NCT00333931	Not specified	UNKNOWN	Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression
NCT00774306	Not specified	TERMINATED	Antiepileptic Drugs and Vascular Risk Markers
NCT03096522	Not specified	UNKNOWN	Randomized Trial on the Effect of Topical Phenytoin on Healing After Fistulotomy
NCT03196466	Not specified	COMPLETED	Population Pharmacokinetics of Antiepileptic in Pediatrics
NCT03269214	Not specified	COMPLETED	Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible
NCT03632915	Not specified	COMPLETED	Pharmacokinetics of Antiepileptics in Patients on CRRT
NCT05542589	Not specified	COMPLETED	Efficacy of Phenytoin Phonophoresis on Pressure Ulcer Healing
NCT06067412	Not specified	COMPLETED	Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health,Faisalabad
NCT06312254	Not specified	COMPLETED	Pharmacological Modulation of Peripheral Nerve Excitability

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (3) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for phenytoin and CYP2C9	DPWG	CYP2C9	yes	yes
Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, H	CPIC	CYP2C9;HLA-B	yes	yes
Annotation of DPWG Guideline for phenytoin and HLA-B	DPWG	HLA-B		yes

PharmGKB also curates 36 clinical and 302 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

134 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
AMIODARONE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
BROMPHENIRAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
CHLORPHENIRAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
CHLORPROMAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
COCAINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DESIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DIBUCAINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DICYCLOMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DILTIAZEM	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DIPHENHYDRAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
DROPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
FELODIPINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
FLUPHENAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
HALOPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
LAMOTRIGINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
LEVORPHANOL	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
LOPERAMIDE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
MEXILETINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
NIFEDIPINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
NISOLDIPINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PHENOXYBENZAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PHENTOLAMINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PIMOZIDE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PRAMOXINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PRAZOSIN	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PRILOCAINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PROMETHAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
PROPARACAINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
QUINIDINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
QUININE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
RESERPINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
TETRABENAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
TETRACAINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
THIORIDAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
TRIFLUOPERAZINE	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
VERAPAMIL	ChEMBL + PubChem	Phase 4 (approved)	SCN2A
ARTICAINE	ChEMBL	Phase 4 (approved)	SCN2A
BENOXINATE	ChEMBL	Phase 4 (approved)	SCN2A
BEPRIDIL	ChEMBL	Phase 4 (approved)	SCN2A
BUPIVACAINE	ChEMBL	Phase 4 (approved)	SCN2A
CINNARIZINE	ChEMBL	Phase 4 (approved)	SCN2A
DIPHENIDOL	ChEMBL	Phase 4 (approved)	SCN2A
ETIDOCAINE	ChEMBL	Phase 4 (approved)	SCN2A
HEXYLCAINE	ChEMBL	Phase 4 (approved)	SCN2A
MIANSERIN	ChEMBL	Phase 4 (approved)	SCN2A
MIBEFRADIL	ChEMBL	Phase 4 (approved)	SCN2A
PHENIRAMINE	ChEMBL	Phase 4 (approved)	SCN2A
PRENYLAMINE	ChEMBL	Phase 4 (approved)	SCN2A
PROMAZINE	ChEMBL	Phase 4 (approved)	SCN2A
PROPOXYCAINE	ChEMBL	Phase 4 (approved)	SCN2A
QUINACRINE	ChEMBL	Phase 4 (approved)	SCN2A
RILUZOLE	ChEMBL	Phase 4 (approved)	SCN2A
SERTINDOLE	ChEMBL	Phase 4 (approved)	SCN2A
YOHIMBINE	ChEMBL + PubChem	Phase 3 (approved)	SCN2A
AJMALINE	ChEMBL	Phase 3	SCN2A
ELECLAZINE	ChEMBL	Phase 3	SCN2A
NITRENDIPINE	ChEMBL	Phase 3	SCN2A
OXETHAZAINE	ChEMBL	Phase 3	SCN2A
TEDISAMIL	ChEMBL	Phase 3	SCN2A
TETRODOTOXIN	ChEMBL	Phase 3	SCN2A
VIXOTRIGINE	ChEMBL	Phase 3	SCN2A
AZACYCLONOL	ChEMBL	Phase 2	SCN2A
BUTACAINE	ChEMBL	Phase 2	SCN2A
BUTACLAMOL	ChEMBL	Phase 2	SCN2A
BUTOXAMINE	ChEMBL	Phase 2	SCN2A
CARCAINIUM CHLORIDE	ChEMBL	Phase 2	SCN2A
CIFENLINE	ChEMBL	Phase 2	SCN2A
COLFORSIN	ChEMBL	Phase 2	SCN2A
CYCLOMETHYCAINE	ChEMBL	Phase 2	SCN2A
DEXPROPRANOLOL	ChEMBL	Phase 2	SCN2A
DEXTRORPHAN	ChEMBL	Phase 2	SCN2A
DILAZEP	ChEMBL	Phase 2	SCN2A
DIMETHISOQUIN	ChEMBL	Phase 2	SCN2A
DIPERODON	ChEMBL	Phase 2	SCN2A
DS-1971	ChEMBL	Phase 2	SCN2A
ELPETRIGINE	ChEMBL	Phase 2	SCN2A
FLUNARIZINE	ChEMBL	Phase 2	SCN2A
FLUPERAMIDE	ChEMBL	Phase 2	SCN2A
FUNAPIDE	ChEMBL	Phase 2	SCN2A
GALLOPAMIL	ChEMBL	Phase 2	SCN2A
HEXOBENDINE	ChEMBL	Phase 2	SCN2A
LEVOPROPRANOLOL	ChEMBL	Phase 2	SCN2A
MEPRYLCAINE	ChEMBL	Phase 2	SCN2A
PARETHOXYCAINE	ChEMBL	Phase 2	SCN2A
PF-05089771	ChEMBL	Phase 2	SCN2A
PHENACAINE	ChEMBL	Phase 2	SCN2A
PIPEROCAINE	ChEMBL	Phase 2	SCN2A
PIPEROXAN	ChEMBL	Phase 2	SCN2A
PROADIFEN	ChEMBL	Phase 2	SCN2A
SIPATRIGINE	ChEMBL	Phase 2	SCN2A
SPIPERONE	ChEMBL	Phase 2	SCN2A
TIAPAMIL	ChEMBL	Phase 2	SCN2A
ZOLAMINE	ChEMBL	Phase 2	SCN2A
Baclofen	PubChem	Approved	SCN2A
Benzocaine	PubChem	Approved	SCN2A
Buspirone	PubChem	Approved	SCN2A
Caffeine	PubChem	Approved	SCN2A